DICE: Dual mTorc Inhibition in advanCed/recurrent Epithelial ovarian cancer resistant to standard treatment—a study protocol for a randomised trial investigating a novel therapy called TAK228

BACKGROUND: The standard initial treatment for ovarian cancer is surgery and platinum-based chemotherapy and potentially maintenance therapy with avastin or inhibitors of poly-ADP ribose polymerase (PARP). While a proportion of women are cured by this approach, the vast majority will relapse and bec...

Descripción completa

Detalles Bibliográficos
Autores principales: Fiorentino, Francesca, Krell, Jonathan, de la Rosa, Consuelo Nohpal, Webber, Lee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980506/
https://www.ncbi.nlm.nih.gov/pubmed/35382842
http://dx.doi.org/10.1186/s13063-022-06201-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980506/
https://www.ncbi.nlm.nih.gov/pubmed/35382842
http://dx.doi.org/10.1186/s13063-022-06201-3

Ejemplares similares